Michael Lotze

Company: University of Pittsburgh Department of Medicine

Job title: Professor - Department of Surgery, Immunology, Bioengineering

Bio:

Michael T. Lotze, MD, FACS is Professor of Surgery, Immunology, and Bioengineering; Director of the DAMP Laboratories at the UPMC Hillman Cancer Center; and Sr. Advisor for the Immune Transplant and Therapy Center within the University of Pittsburgh Medical Center Enterprises. His research work includes modern immunotherapy and gene therapy, dendritic cell, T cell, and cytokine therapies, and investigation of the role of mitochondria, metabolism, and unscheduled cell death in cancer. Dr. Lotze has worked in the field of immunology and clinical medicine for over 40 years and has had the opportunity to personally review and advance the work of individuals developing translational research, particularly within cancer.

Dr. Lotze is the co-inventor of 10 patents in dendritic cell vaccines and antigen discovery, 13 patents in tumor infiltrating lymphocyte therapy (while CSO at Iovance), additional patents at Nurix Therapeutics where he served as Chief Cell Therapy Officer 2020-2023. He is an award-winning NCI-trained scientist (1978-1990), the inaugural Director of Surgical Oncology at Pitt (1990-2000), former Vice President of Research at GlaxoSmithKline (2001), founding director of the UPCI Academy, former Chief Scientific Officer at Lion/Iovance Biotherapeutics, former CCO at Nurix Therapeutics, and innovative educator as a prolific clinician-scientist/tumor immunologist with over 500 publications and several books.

Seminars:

Understanding the Art & Science of TIL Therapy by Reframing Immunity & Resistance 9:00 am

Reframing tumor immunity with a new model: I before E: inflammation, inception, initiation, followed by immune editing with elimination, equilibrium, and escape Introducing pre- and post-TIL strategies to enhance the number and quality of TIL and overcome resistance Emphasizing the bespoke nature of TIL as a scientific advantage, and a strengthRead more

day: Conference Day Two AM